CTSA Hubs are uniquely positioned to lead the response to a national health crisis such as COVID-19.

**HIGHLIGHTS**
- Multi-disciplinary effort to develop and obtain FDA approval for COVID-19 saliva test
- ICTS Director, William Powderly, serves as protocol chair for national ACTIV-1 Immune Modulators trial
- Biorepository distributed 15,655 samples from 672 participants to more than 20 investigators
- Community Advisory Board consulted on recruitment of underrepresented minorities for vaccine research, testing in schools for vulnerable populations, genetic conditions revealed during COVID-19 research
- Awarded pilot funding to 11 COVID-19 projects
- Phase III vaccine trials at Washington University and partner institution Saint Louis University
- 200 COVID-19 research projects submitted to the ICTS portal for basic, clinical and data research

**CONTACT**
Christina Buckel, MSW
buckelcm@wustl.edu